XORTX Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	2020 - 2016
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Jan '22 Jan 1, 2022	2021 - 2017
Net Income	-2.66	-3.31	-2.16	-7.72	-1.58	Upgrade
Depreciation & Amortization	0.11	0.12	0.14	0.06	0.01	Upgrade
Asset Writedown & Restructuring Costs	0	-	-	-	-	Upgrade
Stock-Based Compensation	0.03	0.12	0.12	0.49	0.46	Upgrade
Other Operating Activities	-0.59	-0.72	-3.66	-2.47	-2.61	Upgrade
Change in Accounts Receivable	-0.06	0.04	0.02	-0.04	-0.03	Upgrade
Change in Accounts Payable	0.24	-0.13	-1.19	0.89	-0.26	Upgrade
Change in Other Net Operating Assets	0.16	0.21	0.14	0.62	-0.79	Upgrade
Operating Cash Flow	-2.77	-3.68	-6.58	-8.17	-4.8	Upgrade
Capital Expenditures	-	-	-0	-0.02	-	Upgrade
Sale (Purchase) of Intangibles	-0.06	-0.04	-0.04	-0.03	-0.03	Upgrade
Other Investing Activities	-0.24	-	-	-	-	Upgrade
Investing Cash Flow	-0.29	-0.04	-0.05	-0.05	-0.03	Upgrade
Long-Term Debt Repaid	-0.09	-0.07	-0.07	-0.02	-	Upgrade
Net Debt Issued (Repaid)	-0.09	-0.07	-0.07	-0.02	-	Upgrade
Issuance of Common Stock	2.26	3.52	0	5	20.07	Upgrade
Other Financing Activities	-0.74	-0.67	-0.3	-1.07	-0.7	Upgrade
Financing Cash Flow	1.43	2.78	-0.36	3.91	19.37	Upgrade
Foreign Exchange Rate Adjustments	0.03	-0.04	0	-0.14	0.2	Upgrade
Net Cash Flow	-1.61	-0.97	-6.99	-4.44	14.74	Upgrade
Free Cash Flow	-2.77	-3.68	-6.59	-8.19	-4.8	Upgrade
Free Cash Flow Per Share	-0.58	-1.28	-3.32	-5.53	-4.39	Upgrade
Levered Free Cash Flow	-1.86	-1.11	-3.67	-3.8	-0.83	Upgrade
Unlevered Free Cash Flow	-1.86	-1.11	-3.67	-3.8	-0.82	Upgrade
Change in Working Capital	0.34	0.12	-1.03	1.47	-1.08	Upgrade

Source: S&P Capital IQ. Standard template. Financial Sources.